Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Advanced Prostate Cancer: AUA/SUO Guideline (2026)
Using AUA Guidelines
Access to AUA guidelines is provided free for individuals’ clinical use only. Anyone accessing AUA guidelines for any other purpose must obtain a license in advance. Licenses for academic, research and educational purposes can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to, and limited authorized use of AUA guidelines is a member benefit. Members are granted a limited license to access and use the AUA Guidelines for their individual, non-commercial use, for clinical, academic, educational, and research purposes, in accordance with the AUA Guidelines Terms and Conditions of Use. Members who wish to use the Guidelines for any other purpose, or in any manner not authorized by this limited license grant or by the AUA Guidelines Terms and Conditions of Use must request and obtain a license/permission in advance. Licenses for business or institutional academic, research and educational related purposes (e.g., use in course packs or for employer-sponsored research) can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to AUA guidelines is provided free for individual clinical use only, in accordance with the AUA Guidelines Terms and Conditions of Use. Anyone accessing AUA guidelines for any other purpose must obtain a license/permission in advance. Licenses for academic, research and educational purposes (e.g., in course packs or employer-sponsored research) can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to AUA guidelines is provided free for health care providers for their individual clinical use only. Patients and the general public are provided a summary of the guidelines. Patients who wish to discuss the full guidelines should consult with their healthcare provider.
Guideline Resources
Unabridged PDF for this Guideline
Amendment Summary for this Guideline
Algorithm for this Guideline
The Journal of Urology® Articles
Purpose
Prostate cancer is the most common solid organ malignancy for men in the U.S. and remains the second leading cause of cancer deaths for this population. Importantly, the incidence of advanced stage disease including metastatic hormone-sensitive prostate cancer (mHSPC) has been increasing by about 5% per year in recent years. Prostate cancer deaths are typically the result of progression to metastatic castration-resistant prostate cancer (mCRPC). Rapid therapeutic advances in the treatment landscape for mHSPC and mCRPC render treatment decisions and sequencing increasingly complex. It is against this backdrop that the Panel provides evidence-based guidance for treatment of men with advanced prostate cancer and looks to the future with cautious optimism.
Key Takeaways
Clinicians treating men with advanced prostate cancer are challenged with the rapidly evolving prostate cancer landscape given the approval of new classes of agents for use in various prostate cancer disease states. The increasing complexity of advanced prostate cancer management underscores the need for the current clinical practice guideline, developed to provide a rational basis for treatment of patients with advanced disease, based on currently available published data. To assist in clinical decision-making, guideline recommendations are furnished according to disease states across the entire continuum of advanced prostate cancer:
- Early evaluation and patient counseling
- Prognosis and treatment of
- Biochemical recurrence without metastatic disease after exhaustion of local treatment options
- Metastatic hormone-sensitive prostate cancer
- Non-metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer
- Bone health
Create a free account to access expanded content and resources.
AUA Clinical Practice Guidelines are developed by multidisciplinary panels of experts based on rigorous systematic review of current urologic research.
| Free Resources | |
 |
Prostate Cancer Patient Resources |
|
Urology A-Z Advanced Prostate Cancer Web Article |
| Login to Continue | |
| Member Benefit | |
|
Unabridged PDF for this Guideline |
|
Amendment Summary for this Guideline |
|
Algorithm for this Guideline |
|
The Journal of Urology® Articles |